158 related articles for article (PubMed ID: 12637401)
1. Impact of DOTS compared with DOTS-plus on multidrug resistant tuberculosis and tuberculosis deaths: decision analysis.
Sterling TR; Lehmann HP; Frieden TR
BMJ; 2003 Mar; 326(7389):574. PubMed ID: 12637401
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness of treating multidrug-resistant tuberculosis.
Resch SC; Salomon JA; Murray M; Weinstein MC
PLoS Med; 2006 Jul; 3(7):e241. PubMed ID: 16796403
[TBL] [Abstract][Full Text] [Related]
3. Decline in rates of acquired multidrug-resistant tuberculosis after implementation of the directly observed therapy, short course (DOTS) and DOTS-Plus programmes in Taiwan.
Chien JY; Lai CC; Tan CK; Chien ST; Yu CJ; Hsueh PR
J Antimicrob Chemother; 2013 Aug; 68(8):1910-6. PubMed ID: 23580558
[TBL] [Abstract][Full Text] [Related]
4. Impact of an effective multidrug-resistant tuberculosis control programme in the setting of an immature HIV epidemic: system dynamics simulation model.
Atun RA; Lebcir R; Drobniewski F; Coker RJ
Int J STD AIDS; 2005 Aug; 16(8):560-70. PubMed ID: 16105192
[TBL] [Abstract][Full Text] [Related]
5. Directly observed treatment for multidrug-resistant tuberculosis: an economic evaluation in the United States of America and South Africa.
Wilton P; Smith RD; Coast J; Millar M; Karcher A
Int J Tuberc Lung Dis; 2001 Dec; 5(12):1137-42. PubMed ID: 11769772
[TBL] [Abstract][Full Text] [Related]
6. Clinical outcome of individualised treatment of multidrug-resistant tuberculosis in Latvia: a retrospective cohort study.
Leimane V; Riekstina V; Holtz TH; Zarovska E; Skripconoka V; Thorpe LE; Laserson KF; Wells CD
Lancet; 2005 Jan 22-28; 365(9456):318-26. PubMed ID: 15664227
[TBL] [Abstract][Full Text] [Related]
7. [Tuberculosis in Poland, Europe, and world. Part II--mortality, drug resistance and HIV infection].
Zielonka TM
Pol Merkur Lekarski; 2006 Sep; 21(123):253-61. PubMed ID: 17163187
[TBL] [Abstract][Full Text] [Related]
8. From multidrug-resistant tuberculosis to DOTS expansion and beyond: making the most of a paradigm shift.
Kim JY; Mukherjee JS; Rich ML; Mate K; Bayona J; Becerra MC
Tuberculosis (Edinb); 2003; 83(1-3):59-65. PubMed ID: 12758190
[TBL] [Abstract][Full Text] [Related]
9. Surveillance of Mycobacterium tuberculosis susceptibility to second-line drugs in Hong Kong, 1995-2002, after the implementation of DOTS-plus.
Kam KM; Yip CW
Int J Tuberc Lung Dis; 2004 Jun; 8(6):760-6. PubMed ID: 15182147
[TBL] [Abstract][Full Text] [Related]
10. Impact of DOTS and DOTS-plus on multidrug resistant TB: DOTS-plus strengthens, not weakens, DOTS programmes.
Nardell EA
BMJ; 2003 Jul; 327(7407):164; author reply 164. PubMed ID: 12869471
[No Abstract] [Full Text] [Related]
11. Domestic returns from investment in the control of tuberculosis in other countries.
Schwartzman K; Oxlade O; Barr RG; Grimard F; Acosta I; Baez J; Ferreira E; Melgen RE; Morose W; Salgado AC; Jacquet V; Maloney S; Laserson K; Mendez AP; Menzies D
N Engl J Med; 2005 Sep; 353(10):1008-20. PubMed ID: 16148286
[TBL] [Abstract][Full Text] [Related]
12. Treatment outcome cohort analysis in an integrated DOTS and DOTS-Plus TB program in Latvia.
Riekstina V; Leimane V; Holtz TH; Leimans J; Wells CD
Int J Tuberc Lung Dis; 2007 May; 11(5):585-7. PubMed ID: 17439686
[TBL] [Abstract][Full Text] [Related]
13. Does DOTS work in populations with drug-resistant tuberculosis?
DeRiemer K; García-García L; Bobadilla-del-Valle M; Palacios-Martínez M; Martínez-Gamboa A; Small PM; Sifuentes-Osornio J; Ponce-de-León A
Lancet; 2005 Apr 2-8; 365(9466):1239-45. PubMed ID: 15811457
[TBL] [Abstract][Full Text] [Related]
14. Prevalence of drug resistance under the DOTS strategy in Hyderabad, South India, 2001-2003.
Anuradha B; Aparna S; Hari Sai Priya V; Vijaya Lakshmi V; Akbar Y; Suman Latha G; Murthy KJ
Int J Tuberc Lung Dis; 2006 Jan; 10(1):58-62. PubMed ID: 16466038
[TBL] [Abstract][Full Text] [Related]
15. Risk of acquired drug resistance during short-course directly observed treatment of tuberculosis in an area with high levels of drug resistance.
Cox HS; Niemann S; Ismailov G; Doshetov D; Orozco JD; Blok L; Rüsch-Gerdes S; Kebede Y
Clin Infect Dis; 2007 Jun; 44(11):1421-7. PubMed ID: 17479936
[TBL] [Abstract][Full Text] [Related]
16. DOTS and DOTS-plus: not the only answer.
Farmer P
Ann N Y Acad Sci; 2001 Dec; 953():165-84. PubMed ID: 11795410
[TBL] [Abstract][Full Text] [Related]
17. Prevalence of multidrug-resistant pulmonary tuberculosis in counties with different duration of DOTS implementation in rural China.
Hu Y; Mathema B; Wang W; Hoffner S; Kreiswirth B; Xu B
Microb Drug Resist; 2008 Sep; 14(3):227-32. PubMed ID: 18707239
[TBL] [Abstract][Full Text] [Related]
18. Clinical and programmatic considerations in the treatment of MDR-TB in children: a series of 16 patients from Lima, Peru.
Mukherjee JS; Joseph JK; Rich ML; Shin SS; Furin JJ; Seung KJ; Sloutsky A; Socci AR; Vanderwarker C; Vasquez L; Palacios E; Guerra D; Viru FA; Farmer P; Del Castillo HE
Int J Tuberc Lung Dis; 2003 Jul; 7(7):637-44. PubMed ID: 12870684
[TBL] [Abstract][Full Text] [Related]
19. Isolation of Mycobacterium tuberculosis from sputum of tribal, non-tribal pulmonary tuberculosis patients of Andaman & Nicobar islands by conventional culture method and assessment of first line anti-tuberculosis drug susceptibility patterns.
Mandal A; Parthasarathy G; Burma SP; Sugunan AP; Vijayachari P
Indian J Tuberc; 2015 Jan; 62(1):23-8. PubMed ID: 25857562
[TBL] [Abstract][Full Text] [Related]
20. Beyond DOtS: avenues ahead in the management of tuberculosis.
Chaudhury RR; Thatte U
Natl Med J India; 2003; 16(6):321-7. PubMed ID: 14765625
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
